博利康尼及异丙托溴胺氧驱雾化吸入治疗慢性阻塞性肺病急性加重期疗效观察

Treatment of chronic obstructive pulmonary disease in the acute anabasis with terbutaline and ipratropium bromide oxygen atomizing inhalation

目的探讨氧驱雾化吸入博利康尼和异丙托溴胺治疗慢性阻塞性肺病COPD急性加重期的疗效。方法采用前瞻性随机对照方法 ,将172例Ⅱ级和Ⅲ级COPD急性加重期患者随机分为2组。A组:博利康尼溶液5 mg加生理盐水2 ml氧驱雾化吸入10 min;B组:博利康尼5 mg加异丙托溴胺0.5 mg加生理盐水2 ml氧驱雾化吸入10 min。每组分别于早、晚2次雾化吸入,用RSFJ-1000肺功能仪测定用药后30 min及3h的最大呼气流速(PEF),并与治疗前相比较。结果 A组吸入治疗后30 min PEF较治疗前明显增高,P<0.05;3小时PEF较治疗前增高不明显(P>0.05);B组吸入治疗后30 min明显增高,180 min增高更明显(P<0.05);A、B组治疗后30 min比较无显著性差异(P>0.05),治疗后3h比较有显著性差异(P<0.05)。结论氧驱雾化吸入博利康尼、异丙托溴胺可明显改善COPD急性期PEF,比单用博利康尼效果更好、持续时间更长。

Objective To explore the therapeutic efficacy of terbutaline and ipartropium bromide oxygen atomizing inhalation in treating chronic obstructive pulmonary disease（COPD） in the acute anabasis.Methods We adopted the prospective random comparison method and divided the 172 patients of level II and level III COPD in the acute anabasis into 2 groups.Group A： oxygen atomizing inhalation for 10 min of terbutaline solution 5 mg plus normal saline 2 ml;Group B： oxygen atomizing inhalation for 10 min of terbutaline solution 5 mg and ipartropium bromide solution 0.5 mg plus normal saline 2 ml.The patient＇s peak expiratory flow（PEF） was measured at 30 min and 3 h,respectively,since the measurement of drug usage with RSFJ-1000 lung function unit and compared to that prior to treatment.Results PEF at 30 min after treatment was obviously greater than that before treatment（P〈0.05）.There was no difference between group A and group B at 30 min after treatment（P〉0.05）,but great variance exists between the two groups at 3h since treatment（P〈0.05）.Conclusion Terbutaline and ipartropium bromide oxygen atomizing inhalation can noticeably improve the maximum respiratory flow rate of patients with the chronic obstructive pulmonary disease in the acute anabasis.